PharmAla Biotech (MDMA): Two Transactions, One Strategy: Unlocking Pipeline Value Through Structured Partnerships

In this episode of Healthcare Happenings, Nick Kadysh, Founding CEO and President of PharmAla Biotech (CSE: MDMA / OTCQB: MDXXF), joins host Tim Gerdeman and WTR healthcare analyst Robert Sassoon to discuss two recently announced transactions. The first is the formation of Restora Neuroscience, a special purpose vehicle created to advance APA01, a non-controlled neurology molecule, through a preclinical partnership with Datiba. The second is a term sheet with Jupiter Neurosciences for the exclusive U.S. licensing of ALA-002, PharmAla's next-generation MDMA therapeutic, in a deal valued at over $100 million in potential milestones and royalties. The conversation covers deal structure, partner selection, key investor milestones across both transactions, and how this partnership-driven model allows PharmAla to advance its pipeline while maintaining its position as a leading global supplier of clinical-grade MDMA.